mRNA technology for next generation treatments
BioNTech is building platforms in 3 therapeutic areas using a variety of mRNA technologies to create pharmacologically optimized protein coding RNAs for targeted in vivo delivery
- Cancer immunotherapies
- Infectious disease vaccines
- Protein replacement
BioNTech is part of the EAVI2020 consortium for the development of an effective HIV vaccine. BioNTech will develop novel, highly immunogenic, prophylactic and therapeutic vaccine candidates based on our A.I.R. technology platform. For more information visit the EAVI2020 Website.